|1.||Dubler, Erich: 1 article (06/2003)|
|2.||Buschmann, Ralph: 1 article (06/2003)|
|3.||Schmalle, Helmut W: 1 article (06/2003)|
01/01/1987 - "Of the compounds tested, budotitane was the most effective in terms of decrease in tumor weight and number and in increasing the lifespan of the treated animals. "
06/01/1989 - "Assessment of the preclinical activity of budotitane in three different transplantable tumor systems, its lack of mutagenicity, and first results of clinical phase I studies."
12/01/1986 - "INN: budotitane) are active against several transplantable tumors. "
06/01/2003 - "The molecular tumor inhibiting titanium compound budotitane [Ti(IV)(bzac)(2)(OEt)(2)] (1) and its dichloro-derivative [Ti(IV)(bzac)(2)Cl(2)] (2) (bzac=1-phenylbutane-1,3-dionate) have been crystallized and characterized by X-ray crystallography and further physical methods. "
06/01/1989 - "The antitumor activity of budotitane was investigated in three different tumor systems--the transplantable murine ascitic-colon-adenocarcinoma MAC 15A, the TD-osteosarcoma of the rat, and the intramuscularly transplanted murine sarcoma 180. "
|2.||Osteosarcoma (Osteogenic Sarcoma)
|4.||Cardiac Arrhythmias (Arrythmia)